Name: IDT Australia (IDT) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

IDT

Pharmaceuticals, Biotechnology & Life Sciences

IDT Australia

Short interest: 0.11%; +0.10 pp 30d; as of 21 May 2026
Reported shorts: 449.6K
Shares on issue: 427.426M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About IDT Australia

IDT Australia is a Melbourne-based Contract Development and Manufacturing Organisation (CDMO) with over 50 years of experience. They offer end-to-end services from pre-clinical development to commercial-scale supply, covering active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Their cGMP facility supports oral medicines and sterile injectables, serving both local and international markets.

Company profile →

IDT Australia (ASX:IDT) has 0.11% of its shares on issue reported as short positions as of 21 May 2026, or about 449,649 shares. Over the past 30 days that figure has risen 0.10 percentage points, and over 90 days it has risen 0.10 percentage points. Its highest recorded short interest was 0.22% in June 2023. IDT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads IDT today

Zanger BreakoutWatchScore 10rank 1695 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 6rank 1674 of 1716
Crowded-Short BreakoutWatchScore 14rank 702 of 1502
Quality compoundersWatchScore 7rank 1511 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

IDT fundamentals

In the year to 30 Jun 2026, IDT Australia (ASX:IDT) recorded revenue of A$20.4M and a net loss after tax of A$2.7M. A year earlier it recorded revenue of A$19.2M and a net loss after tax of A$8.1M. Year-on-year growth: revenue +5.9% (FY). Net margin −13.3%, return on equity −13.3% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →